HbA1c News and Research

RSS

Study analyses impact of one-off advice session and ongoing support for patients with T2D

Research led by the University of Leicester concludes that people newly diagnosed with Type 2 diabetes need ongoing advice from GPs sustained over a number of years rather than a one-off session when they are first diagnosed.

14 Jun 2012

Almased helps patients with type 2 diabetes lose weight, gain better sugar control

A pilot study shows that a protein-rich meal replacement made from soy, yogurt, and honey (Almased) helps patients with type 2 diabetes lose weight, gain better control of their blood sugar, and decrease their daily insulin dose. Patients in the study also lowered their body mass index (BMI), waist and hip circumference, and fasting glucose levels, while improving their HDL-cholesterol and triglycerides.

12 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

GLP-1 receptor agonist boosts glycemic control in Asian patients

Adding once-daily lixisenatide to basal insulin treatment is effective at improving glycemic control in Asian patients with Type 2 diabetes, show study findings.

6 Jun 2012

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids.

From Baxter International Inc. 28 May 2012

Lilly, Boehringer Ingelheim receive positive opinion from EMA for Jentadueto

Boehringer Ingelheim and Eli Lilly and Company today announced that they have received a positive opinion from the European Medicines Agency's medicinal committee recommending approval of Jentadueto,which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes who need to improve control of their blood glucose.

28 May 2012

Linagliptin safe and effective for African American patients with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.

25 May 2012

Severity of nocturnal hypoxemia and SDB independently predict both T2DM and HbA1c levels

The severity of sleep disordered breathing and nocturnal hypoxemia independently predict both glycosylated hemoglobin (HbA1c) levels and type 2 diabetes mellitus (T2DM), according to a new study.

24 May 2012

Hygieia’s DIGS automatically adjusts insulin dosage in patients with diabetes

Newly published results from a clinical study of the Diabetes Insulin Guidance System (DIGS-), under development by Hygieia, Inc., demonstrate DIGS' potential to improve blood glucose control for insulin-using patients with type 2 or type 1 diabetes. DIGS automatically adjusted insulin dosage based on each individual's reported blood glucose results.

10 May 2012

Bariatric surgery effectively controls diabetes

Overweight, diabetic patients who underwent bariatric surgery achieved significant improvement or remission of their diabetes, according to new research from Cleveland Clinic.

27 Mar 2012

Bariatric surgery better than standard medical treatment for severe type 2 diabetes

In the first published study of its kind, researchers from the Catholic University/Policlinico Gemelli in Rome, Italy, and NewYork-Presbyterian/Weill Cornell Medical Center found that bariatric surgery dramatically outperforms standard medical treatment of severe type 2 diabetes.

27 Mar 2012

Research roundup: Unequal 'culture of quality' in hospitals; Peer-support for stressed doctors

Comparison Of Hospital Performance In Trauma Vs Emergency And Elective General Surgery –This study compared outcomes of trauma patients and patients having either elective or emergency surgery in the same hospital. Researchers thought that "hospital performance reflected institutional culture, and, thus, would be similar across all services."

23 Mar 2012

Peer mentor intervention improves glucose control in African American veterans with diabetes

by peer mentors has a statistically significant effect on improving glucose control in African American veterans with diabetes, according to a study by researchers at the Perelman School of Medicine at the University of Pennsylvania and the Philadelphia VA Center for Health Equity Research and Promotion.

20 Mar 2012

Soy-based S-equol lowers HbA1c, LDL cholesterol and improves vascular stiffness

A 12-week treatment of the fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c (HbA1c), LDL cholesterol and improved vascular stiffness, all factors that occur as part of metabolic syndrome, according to a first-of-its-kind peer-reviewed study reported in a poster at the Women's Health 2012 annual meeting.

19 Mar 2012

Experts highlight latest advances in use of biomarkers in various diseases

Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.

16 Mar 2012

H. pylori bacteria associated with elevated levels of HbA1c

A new study by researchers at NYU Langone Medical Center reveals that the presence of Helicobacter pylori (H. pylori) bacteria is associated with elevated levels of glycosylated hemoglobin (HbA1c), an important biomarker for blood glucose levels and diabetes.

15 Mar 2012

Lowering HbA1c cutoffs increases health benefits of type 2 diabetes preventive interventions

The American Diabetes Association recommends hemoglobin A1c (HbA1c) testing as one basis for identifying diabetes and prediabetes.

13 Mar 2012

TAK-875 as effective as glimepiride in treating type 2 diabetes

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012

HbA1c News and Research

Study analyses impact of one-off advice session and ongoing support for patients with T2D

Almased helps patients with type 2 diabetes lose weight, gain better sugar control

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

GLP-1 receptor agonist boosts glycemic control in Asian patients

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Lilly, Boehringer Ingelheim receive positive opinion from EMA for Jentadueto

Linagliptin safe and effective for African American patients with type 2 diabetes

Severity of nocturnal hypoxemia and SDB independently predict both T2DM and HbA1c levels

Hygieia’s DIGS automatically adjusts insulin dosage in patients with diabetes

Bariatric surgery effectively controls diabetes

Bariatric surgery better than standard medical treatment for severe type 2 diabetes

Research roundup: Unequal 'culture of quality' in hospitals; Peer-support for stressed doctors

Peer mentor intervention improves glucose control in African American veterans with diabetes

Soy-based S-equol lowers HbA1c, LDL cholesterol and improves vascular stiffness

Experts highlight latest advances in use of biomarkers in various diseases

H. pylori bacteria associated with elevated levels of HbA1c

Lowering HbA1c cutoffs increases health benefits of type 2 diabetes preventive interventions

TAK-875 as effective as glimepiride in treating type 2 diabetes

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News